First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine

@article{Buck2008FirstDO,
  title={First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine},
  author={A. Buck and M. Bommer and M. Juweid and G. Glatting and S. Stilgenbauer and F. Mottaghy and M. Schulz and T. Kull and D. Bunjes and P. Möller and H. D{\"o}hner and S. Reske},
  journal={Journal of Nuclear Medicine},
  year={2008},
  volume={49},
  pages={1756 - 1762}
}
Acute myeloid leukemia (AML) is a neoplasm of hematopoietic stem cells with partial or complete loss of the ability to differentiate but with preserved proliferation capacity. The aim of our study was to evaluate if the in vivo proliferation marker 3′-deoxy-3′-18F-fluorothymidine (FLT) is suitable for visualizing leukemia manifestation sites and if 18F-FLT is a surrogate marker for disease activity. Methods: In this pilot study, 10 patients with AML underwent pretherapeutic imaging with 18F-FLT… Expand
Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CT
TLDR
This preliminary study suggests that 18F-FLT PET/CT may be valuable as a noninvasive tool for early assessment of the response to treatment and may provide prognostic value for survival in patients with AML. Expand
Effect of radiotherapy and chemotherapy on bone marrow activity: a 18F–FLT–PET study
TLDR
It is concluded that 18F–FLT–PET is a potential noninvasive tool that can be used in the assessment of quantification of cellular division in the hematopoietic organ. Expand
Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.
TLDR
FLT PET imaging during induction chemotherapy may serve as an early biomarker of treatment response in AML, suggesting that FLT PET scans acquired as early as 2 days after chemotherapy initiation may be predictive of clinical response. Expand
18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia
TLDR
Since most of these patients relapsed within a short period of time after initiation of therapy or had refractory disease, the detection of extramedullary disease with 18Fluoro-deoxy-Glucose Positron Emission Tomography/Computed Tomography might be helpful in the development of individual treatment algorithms for these high-risk patients. Expand
The role of F-18-fluorothymidine PET in oncology
TLDR
Preliminary results seem to indicate a promising role for this tracer in oncology imaging, especially in therapy response evaluation and in brain tumors; it is also associated with a lower rate of false-positive results due to inflammation. Expand
The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial
TLDR
Metabolic activity in EM AML may persist even beyond the time point of hematologic remission, a finding that merits further prospective investigation to explore its prognostic relevance. Expand
Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
TLDR
Methods for in vivo assessment of the proliferative activity in preclinical and clinical studies are described with a focus on early monitoring response to therapy. Expand
Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
TLDR
Investigation of the usefulness of (18)F-FLT PET for imaging human leukemia-tumor bearing mice, compared with fluorine-18-fluorodesoxyglucose ((18)f-FDG PET), and quantitative and semi-quantitative uptake measurements resulting from cell lines and PET imaging respectively, suggested a promising potential of ( 18)F -FLT for metabolic imaging of human chronic myeloid leukemia. Expand
Homing of cytokine-induced killer cells during the treatment of acute promyelocytic leukemia
TLDR
The clinical outcome of this small cohort of nine patients supported the efficacy of this regimen: two patients achieved rapid complete remission after three-cycle treatment, and six patients remained stable, subsequently became sensitive to conventional therapy, and also achieved complete remission. Expand
Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.
TLDR
F-FDG PET/CT is a sensitive, but not specific imaging modality for diagnosing extramedullary AL. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.
TLDR
18F-FLT PET can be used to visualize the proliferative activity of the bone marrow compartment and may be helpful to distinguish separate hematologic disorders. Expand
18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
TLDR
18F-FLT is a promising tracer for the detection and characterization of primary central nervous system tumors and might help to differentiate between low- and high-grade gliomas and might improve early evaluation of treatment effects, especially in patients with high- grade glioma. Expand
Molecular imaging of proliferation in malignant lymphoma.
TLDR
Due to specific imaging of proliferation, FLT may be a superior PET tracer for detection of malignant lymphoma in organs with high physiologic fluorodeoxyglucose uptake and early detection of progression to a more aggressive histology or potential transformation. Expand
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT
TLDR
In a lymphoma xenotransplant model, [18F]FLT detects early antiproliferative drug activity before changes in tumour size are visible, and these findings further support the use of [18FsFLT-PET for imaging early response to treatment in malignant lymphoma. Expand
Detection of extramedullary infiltrates in acute myelogenous leukemia with whole-body positron emission tomography and 2-deoxy-2-[18F]-fluoro-D-glucose.
TLDR
It is suggested that whole-body FDG-PET may be valuable for the detection of EML and for the assessment of chemotherapeutic effects on identified lesions. Expand
Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy
TLDR
A 10-minute FLT-PET scan acquired two weeks after the end of the first course of chemotherapy is useful for predicting longer-term efficacy of chemotherapy regimens for women with breast cancer. Expand
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
TLDR
FLT- PET as an imaging biomarker seems to be predictive of overall survival in bevacizumab and irinotecan treatment of recurrent gliomas, and whether FLT-PET performed as early as 1 to 2 week after starting treatment is as predictive as the study indicates at 6 weeks warrants further investigation. Expand
Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies.
TLDR
The study shows that the in vivo measurement of 2-[(11)C]thymidine in tumors using PET can provide a surrogate marker of proliferation and supports the potential use of the technique in the early assessment of response to antiproliferative cancer treatment. Expand
3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.
TLDR
FLT uptake was specific for malignant lesions and may be used for differential diagnosis of SPNs, assessment of proliferation, and estimation of prognosis. Expand
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.
TLDR
Results suggest that FLT images reflect TK(1) activity and the percentage of cells in S phase, and suggest that inhibition of cell cycle progression prevents FLT uptake and increased TK-1 activity. Expand
...
1
2
3
4
...